Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Legend Biotech's Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $95.2 million for Q4 2025.

• Quarterly Total Non-Current Liabilities fell 72.95% year-over-year to $95.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $95.2 million (down 72.95% YoY) and the FY2025 annual result came in at $95.2 million, down 72.95% from the prior year.
• Total Non-Current Liabilities was $95.2 million for Q4 2025 at Legend Biotech, down from $268.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $388.9 million in Q2 2025 and bottomed at $262860.0 in Q1 2021.
• A 5-year average of $276.2 million and a median of $323.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 143102.85% — and 2025, when it plunged 72.95%.
• Legend Biotech's Total Non-Current Liabilities stood at $124.3 million in 2021, then jumped by 132.36% to $288.9 million in 2022, then surged by 31.83% to $380.8 million in 2023, then decreased by 7.59% to $351.9 million in 2024, then plunged by 72.95% to $95.2 million in 2025.
• Business Quant data shows LEGN's Total Non-Current Liabilities at $95.2 million in Q4 2025, $268.1 million in Q3 2025, and $388.9 million in Q2 2025.